Sensei Biotherapeutics (NASDAQ:FTH) Trading Up 5.3% - Still a Buy?

Key Points

• Sensei Biotherapeutics shares rose 5.3% to approximately $33.69, despite trading volume running 72% below the average session level.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $55 price target—well above the current share price.
• The company beat quarterly EPS expectations, reporting a loss of $2.84 per share versus the anticipated $5.04 loss, while institutional investors own 10.5% of outstanding shares.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) shares shot up 5.3% during mid-day trading on Monday . The company traded as high as $33.39 and last traded at $33.6850. Approximately 57,815 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 209,544 shares. The stock had previously closed at $32.00.

Analysts Set New Price Targets

Several research firms have issued reports on FTH. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a "buy" rating and a $55.00 price target on the stock. Needham & Company LLC started coverage on Sensei Biotherapeutics in a research report on Friday. They set a "buy" rating and a $56.00 target price on the stock. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $51.00 price target for the company. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They issued an "outperform" rating and a $56.00 price objective for the company. Finally, JonesTrading assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.

Sensei Biotherapeutics Stock Performance

The stock has a market capitalization of $881.58 million, a price-to-earnings ratio of -0.24 and a beta of -0.25. The stock has a 50 day moving average of $27.27.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20. As a group, equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current fiscal year.

Insider Buying and Selling at Sensei Biotherapeutics

In related news, major shareholder James Peyer sold 25,000 shares of the firm's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the sale, the insider directly owned 130,142 shares of the company's stock, valued at $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Brian C. Stephenson bought 9,391 shares of the company's stock in a transaction on Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares of the company's stock, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 49,494 shares of company stock worth $1,188,822 over the last three months. Corporate insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock valued at $123,000 after purchasing an additional 1,100 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics in the first quarter worth about $4,188,000. Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics during the 1st quarter valued at about $22,758,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Institutional investors own 10.50% of the company's stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source